Chris Takimoto

Chris Takimoto, MD, PhD, serves as the Global Chief Medical Officer at The START Center for Cancer Research starting October 2024, following a tenure as Chief Medical Officer at IGM Biosciences, Inc. from July 2021 to October 2024. Prior to this, Chris held various leadership roles in significant organizations, including Senior Vice President at Gilead Sciences and Chief Medical Officer at Forty Seven, Inc., specializing in Immuno-Oncology. Significant contributions to oncology stem from positions such as Vice President at Janssen Pharmaceutical Companies, Senior Director of Translational Medicine at Ortho Biotech, and Director of Pharmacology at The START Center for Cancer Care. Academic affiliations include an adjunct professor role at the University of Texas Health Science Center at San Antonio and chairing the Early Therapeutics Committee for the SWOG Cancer Research Network. Chris's educational background includes a dual MD and PhD from Yale, alongside fellowships in Medical Oncology and Clinical Pharmacology.